EUVIMEDEUVIMED entdecken
Open Access

Repurposed Acarbose Targets Nidogen-1 to Remodel the Tumor Stroma and Suppress Portal Vein Tumor Thrombus in Hepatocellular Carcinoma

Tao Han iD, Lujun Chen, Ning Liu, Ying Chen Han, Zhi Zhu, Shuyi Wang, Haoran Song, Ziming Gao, Lin Su, Qilin Hu, Linda Hammerich, Timothy M Pawlik und 14 weitere

Research · 01.01.2026 · 9

DOI: 10.34133/research.1161 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Research, online erschienen am 25.02.2026. Verfasst von Tao Han und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: The National Natural Science Foundation of China, Educational funding of Liaoning Province, Liaoning Provincial Science and Technology Plan Projects.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Portal vein tumor thrombus (PVTT) is among the most lethal complications of hepatocellular carcinoma (HCC), yet its molecular mechanisms and immune features remain poorly characterized. To address this gap, we performed a comprehensive multi-omics analysis of 99 specimens from 47 patients, integrating nCounter profiling, single-cell RNA sequencing, digital spatial profiling, and proteomics to construct the first spatial map of the PVTT microenvironment. These analyses revealed marked intratumoral heterogeneity and enrichment of myofibroblast-like cancer-associated fibroblasts (myCAFs) arising through a macrophage-to-myofibroblast transition. Nidogen-1 (NID1) was identified as a stromal driver of immune barriers, highly expressed in PVTT cores and associated with impaired antitumor immunity. Guided by these mechanistic insights, we repurposed acarbose, a Food and Drug Administration-approved drug, to inhibit the NID1 axis. Functional assays demonstrated that acarbose disrupted myCAF-mediated immune barriers, suppressed PVTT progression, and synergized with anti-programmed death-1 (anti-PD-1) therapy in preclinical models. Furthermore, analysis of an independent clinical cohort of 810 HCC patients revealed a substantially lower incidence of PVTT among those receiving acarbose, underscoring its translational potential. Collectively, these findings establish the immune–stromal landscape of PVTT, uncover NID1-driven stromal remodeling as a mechanism of immune evasion, and highlight drug repurposing as an immediately actionable strategy to improve outcomes in HCC with PVTT.

Autor:innen und Institutionen

  • Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
  • Laboratory of Gastrointestinal Onco-Pathology, Cancer Institute and General Surgery Institute, The First Hospital of China Medical University, Shenyang, China.
  • Department of Pancreatic and Biliary Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
  • Department of Surgical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
  • Shanghai Key Laboratory of Health Identification and Assessment, School of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Department of Hepatology and Gastroenterology, Campus Charité Mitte and Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany.

ORCID-Profile: Tao Han, Heming Li, Kai Li

Förderung

  • The National Natural Science Foundation of China
  • Educational funding of Liaoning Province
  • Liaoning Provincial Science and Technology Plan Projects
  • Shenyang supporting program for young and middle-aged technology innovation talents
  • Shenyang Science and Technology Plan Projects
  • National Key Research and Development Program of China

Zitieren

APA

Han, T., Chen, L., Liu, N., Han, Y. C., Zhu, Z., Wang, S., Song, H., Gao, Z., Su, L., Hu, Q., Hammerich, L., Pawlik, T. M., Zhang, Y., Kudo, M., Li, H., Ma, L., Valabrega, G., Wang, G., Yang, Z., …, & Li, K. (2026). Repurposed Acarbose Targets Nidogen-1 to Remodel the Tumor Stroma and Suppress Portal Vein Tumor Thrombus in Hepatocellular Carcinoma. Research, 9. https://doi.org/10.34133/research.1161

Vancouver

Han T, Chen L, Liu N, Han YC, Zhu Z, Wang S, et al. Repurposed Acarbose Targets Nidogen-1 to Remodel the Tumor Stroma and Suppress Portal Vein Tumor Thrombus in Hepatocellular Carcinoma. Research. 2026;9. doi:10.34133/research.1161

BibTeX
@article{Han2026,
  author = {Han, Tao and Chen, Lujun and Liu, Ning and Han, Ying Chen and Zhu, Zhi and Wang, Shuyi and Song, Haoran and Gao, Ziming and Su, Lin and Hu, Qilin and Hammerich, Linda and Pawlik, Timothy M and Zhang, Yuhan and Kudo, Masatoshi and Li, Hao and Ma, Lei and Valabrega, Giorgio and Wang, Guang and Yang, Zhengqiang and Luo, Qiuhua and Marino, Donatella and Xu, Zihang and Niu, Meng and Chen, Tingsong and Li, Heming and Li, Kai},
  title = {Repurposed Acarbose Targets Nidogen-1 to Remodel the Tumor Stroma and Suppress Portal Vein Tumor Thrombus in Hepatocellular Carcinoma},
  journal = {Research},
  year = {2026},
  volume = {9},
  doi = {10.34133/research.1161}
}
Kostenlos starten →